Results 11 to 20 of about 5,808 (257)

Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy [PDF]

The Journal of Clinical Investigation
Alyssa M. Duffy, Anshika Goenka, Maryam I. Azeem, Azmain Taz, Sayalee V. Potdar, Sara A. Scott, Ellen Marin, Jonathan L. Kaufman, Craig C. Hofmeister, Nisha S. Joseph, Vikas A. Gupta, Sagar Lonial, Ajay K. Nooka, Madhav V. Dhodapkar, Kavita M. Dhodapkar   +14 more
doaj   +4 more sources

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma [PDF]

Journal for ImmunoTherapy of Cancer, 2021
Glioblastoma is the the most common primary brain tumor in adults. Onset of disease is followed by a uniformly lethal prognosis and dismal overall survival. While immunotherapies have revolutionized treatment in other difficult-to-treat cancers, these have failed to demonstrate significant clinical benefit in patients with glioblastoma.
Kirit Singh, Kelly M Hotchkiss, Aditya A Mohan, Jessica L Reedy, John H Sampson, Mustafa Khasraw   +5 more
openaire   +3 more sources

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Journal of Hematology & Oncology, 2023
Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding, Shuyang Sun, Xuan Wang, Xiaomei Yang, Wei Shi, Xianing Huang, Shenxia Xie, Fengzhen Mo, Xiaoqiong Hou, Aiqun Liu, Xiaobing Jiang, Zhuoran Tang, Xiaoling Lu   +12 more
doaj   +1 more source

Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? [PDF]

Clinical and Experimental Immunology, 2023
Summary B and T cells collaborate to drive autoimmune disease (AID). Historically, B- and T-cell (B–T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B-cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis ...
Kavina Shah, Maria Leandro, Mark Cragg, Florian Kollert, Franz Schuler, Christian Klein, Venkat Reddy   +6 more
openaire   +3 more sources

Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy

Haematologica, 2023
T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major clinical challenge. Growing evidence suggests that a complex interplay between immune cells and tumor cells is implicated in the mechanism of action and therefore,
Casey, M, Lee, C, Kwok, WY, Law, SC, Corvino, D, Gandhi, MK, Harrison, SJ, Nakamura, K   +7 more
openaire   +6 more sources

Bispecific T‐cell engagers for cancer immunotherapy [PDF]

Immunology & Cell Biology, 2014
Bispecific T‐cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single‐chain variable fragments (scFv) connected in tandem by a flexible linker. One scFv binds to a T‐
Amelia M, Huehls, Tiffany A, Coupet, Charles L, Sentman   +2 more
openaire   +2 more sources

Generalizable design parameters for soluble T cell receptor-based T cell engagers [PDF]

Journal for ImmunoTherapy of Cancer, 2022
While most biological and cellular immunotherapies recognize extracellular targets, T cell receptor (TCR) therapeutics are unique in their ability to recognize the much larger pool of intracellular antigens found on virus-infected or cancerous cells.
Karen J Froning, Arlene Sereno, Flora Huang, Stephen J Demarest   +3 more
openaire   +3 more sources

The landscape of bispecific T cell engager in cancer treatment

Biomarker Research, 2021
T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major problem. To address this limitation, strategies
Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu   +4 more
doaj   +1 more source

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

Frontiers in Immunology, 2023
The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies. This is attributed to a shortage of
Gianna M. Branella, Gianna M. Branella, Gianna M. Branella, Jasmine Y. Lee, Jasmine Y. Lee, Jasmine Y. Lee, Jennifer Okalova, Jennifer Okalova, Jennifer Okalova, Kiran K. Parwani, Kiran K. Parwani, Kiran K. Parwani, Jordan S. Alexander, Jordan S. Alexander, Raquel F. Arthuzo, Raquel F. Arthuzo, Raquel F. Arthuzo, Andrew Fedanov, Andrew Fedanov, Bing Yu, David McCarty, Harrison C. Brown, Shanmuganathan Chandrakasan, Shanmuganathan Chandrakasan, Brian G. Petrich, Christopher B. Doering, Christopher B. Doering, Christopher B. Doering, H. Trent Spencer, H. Trent Spencer, H. Trent Spencer   +30 more
doaj   +1 more source

Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells [PDF]

Molecular Therapy, 2015
Adoptive immunotherapy with antigen-specific T cells has shown promise for the treatment of malignancies. However, infused T cells are unable to redirect resident T cells, limiting potential benefit. While the infusion of bispecific T-cell engagers can redirect resident T cells to tumors, these molecules have a short half-life, and do not self amplify.
Iwahori, Kota, Kakarla, Sunitha, Velasquez, Mireya P, Yu, Feng, Yi, Zongzhen, Gerken, Claudia, Song, Xiao-Tong, Gottschalk, Stephen   +7 more
openaire   +2 more sources